Invectys

SME

Invectys

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Invectys

Address

Paris, Ile de France, France

Contact

contact@invectys.com

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Invectys

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Invectys last news

08/08/2023

Clinical Trials

Active clinical trials   IVS-3001 in subjects with previously treated Advanced HLA-G-positive solid tumors IVS-3001 is currently being evaluated in clinical trial(s) in patients with HLA-G+ relapsed or refractory solid tumors. This Phase 1/2 trial aims to investigate the safety, tolerability, pharmacokinetics and clinical activity of our anti-HLA-G CAR-T cells in solid tumors expressing HLA-G. […] Cet article Clinical Trials est apparu en premier sur Invectys .

31/07/2023

FDA Grants Fast Track designation to IVS-3001, Invectys' CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma

FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma   Houston, TX, USA, July 31, 2023 – Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the U.S. Food and Drug Administration (FDA) has granted Fast Track […] Cet article FDA Grants Fast Track designation to IVS-3001, Invectys' CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma est apparu en premier sur Invectys .

13/07/2023

Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership

Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership Houston, TX, USA, July 13, 2023 – Invectys, Inc., a clinical-stage immuno-oncology company developing novel therapies for the treatment of advanced cancers, today announces it has initiated the clinical trial of its lead CAR-T program, IVS-3001, in solid tumors. The […] Cet article Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership est apparu en premier sur Invectys .